Study details
Enrolling now
A Study of HLD-0117 in Patients With Metastatic Breast Cancer
Halda Therapeutics OpCo, Inc.
NCT IDNCT07524855ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18+
Sex
Female only
Locations
3 sites in FL, TN, VA
What this study is about
This Phase 1 study is focused on people with breast cancer. The primary outcome being measured is AEs, ECGs, Labs and Clinical Changes.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: AEs, ECGs, Labs and Clinical Changes, Dose Limiting Toxicities (DLTs)
Secondary: Disease Control Rate (DCR), Duration of response (DOR), Objective response rate (ORR), Progression-free survival (rPFS)
Body systems
Oncology